|
Chromadex Corporation (CDXC) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
ChromaDex Corporation (CDXC) Bundle
Suchen Sie, um den intrinsischen Wert von Chromadex Corporation (CDXC) zu bewerten? Unser (CDXC) DCF-Taschenrechner integriert reale Daten mit umfassenden Anpassungsfunktionen, sodass Sie Prognosen anpassen und Ihre Investitionsauswahl verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.3 | 59.3 | 67.4 | 72.1 | 83.6 | 97.1 | 112.8 | 131.0 | 152.2 | 176.7 |
| Revenue Growth, % | 0 | 28.01 | 13.82 | 6.82 | 15.99 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 |
| EBITDA | -29.8 | -18.3 | -25.4 | -16.7 | -3.9 | -31.2 | -36.3 | -42.2 | -49.0 | -56.9 |
| EBITDA, % | -64.33 | -30.95 | -37.73 | -23.24 | -4.66 | -32.18 | -32.18 | -32.18 | -32.18 | -32.18 |
| Depreciation | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 2.5 | 2.9 | 3.4 | 3.9 | 4.6 |
| Depreciation, % | 3.29 | 2.55 | 2.41 | 2.61 | 2.04 | 2.58 | 2.58 | 2.58 | 2.58 | 2.58 |
| EBIT | -31.3 | -19.9 | -27.1 | -18.6 | -5.6 | -33.7 | -39.2 | -45.5 | -52.9 | -61.4 |
| EBIT, % | -67.62 | -33.5 | -40.14 | -25.85 | -6.7 | -34.76 | -34.76 | -34.76 | -34.76 | -34.76 |
| Total Cash | 18.8 | 16.5 | 28.0 | 20.2 | 27.3 | 33.2 | 38.5 | 44.7 | 52.0 | 60.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.2 | 2.7 | 5.2 | 8.5 | 5.2 | 6.8 | 7.9 | 9.2 | 10.7 | 12.4 |
| Account Receivables, % | 4.7 | 4.55 | 7.75 | 11.77 | 6.26 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 |
| Inventories | 11.5 | 11.7 | 13.6 | 14.7 | 14.5 | 19.9 | 23.1 | 26.9 | 31.2 | 36.3 |
| Inventories, % | 24.92 | 19.72 | 20.16 | 20.37 | 17.38 | 20.51 | 20.51 | 20.51 | 20.51 | 20.51 |
| Accounts Payable | 9.6 | 9.4 | 10.4 | 9.7 | 10.2 | 15.1 | 17.6 | 20.4 | 23.7 | 27.5 |
| Accounts Payable, % | 20.79 | 15.94 | 15.45 | 13.43 | 12.24 | 15.57 | 15.57 | 15.57 | 15.57 | 15.57 |
| Capital Expenditure | -.8 | -.1 | -.4 | -.3 | -.1 | -.6 | -.7 | -.8 | -.9 | -1.1 |
| Capital Expenditure, % | -1.63 | -0.23963 | -0.60638 | -0.46357 | -0.1771 | -0.62267 | -0.62267 | -0.62267 | -0.62267 | -0.62267 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -30.6 | -18.4 | -25.5 | -16.3 | -5.6 | -31.9 | -37.0 | -43.0 | -50.0 | -58.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -34.0 | -17.9 | -27.8 | -19.8 | -.1 | -32.0 | -36.7 | -42.6 | -49.5 | -57.5 |
| WACC, % | 14.39 | 14.38 | 14.38 | 14.38 | 14.39 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -142.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -59 | |||||||||
| Terminal Value | -474 | |||||||||
| Present Terminal Value | -242 | |||||||||
| Enterprise Value | -385 | |||||||||
| Net Debt | -24 | |||||||||
| Equity Value | -361 | |||||||||
| Diluted Shares Outstanding, MM | 75 | |||||||||
| Equity Value Per Share | -4.81 |
What You Will Receive
- Pre-Filled Financial Model: ChromaDex Corporation’s (CDXC) actual data provides an accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other critical parameters.
- Real-Time Calculations: Instant updates allow you to view results immediately as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for in-depth forecasts.
Key Features
- Comprehensive CDXC Data: Pre-loaded with ChromaDex Corporation’s historical performance metrics and future projections.
- Customizable Inputs: Tailor revenue growth rates, profit margins, discount rates, tax implications, and capital expenditure estimates.
- Adaptive Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive Interface: Clean, organized, and crafted for both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review ChromaDex Corporation’s (CDXC) pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for ChromaDex Corporation (CDXC)?
- User-Friendly Interface: Perfect for both novice users and seasoned analysts.
- Customizable Inputs: Tailor assumptions easily to suit your financial analysis.
- Real-Time Updates: Instantly view changes to ChromaDex's valuation as you modify inputs.
- Preloaded Data: Comes equipped with ChromaDex's latest financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and financial analysts for making strategic decisions.
Who Should Use This Product?
- Finance Students: Explore advanced valuation methods and apply them using real-time data for ChromaDex Corporation (CDXC).
- Academics: Integrate industry-standard models into your academic projects or research related to ChromaDex Corporation (CDXC).
- Investors: Validate your investment hypotheses and evaluate valuation metrics for ChromaDex Corporation (CDXC).
- Analysts: Enhance your analysis process with a ready-to-use, customizable DCF model tailored for ChromaDex Corporation (CDXC).
- Small Business Owners: Understand the analytical approaches used for evaluating companies like ChromaDex Corporation (CDXC).
What the Template Contains
- Pre-Filled DCF Model: ChromaDex Corporation’s (CDXC) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital specific to ChromaDex Corporation (CDXC).
- Financial Ratios: Evaluate ChromaDex Corporation’s (CDXC) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios for ChromaDex Corporation (CDXC).
- Financial Statements: Annual and quarterly reports for ChromaDex Corporation (CDXC) to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results for ChromaDex Corporation (CDXC).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.